New cyclooxygenase inhibitors

Annals of the Academy of Medicine Singapore

Volumn 30, Issue 2, 2001, Pages 164-169

  Vasoo, S ^b   Ng, Swee Cheng ^a  

^a ALEXANDRA HOSPITAL   (Singapore)

^b NONE

Author keywords

Adverse effects; COX 2 inhibitors; Efficacy

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB;

ANALGESIA; CHRONIC ARTHRITIS; CONFERENCE PAPER; DRUG COST; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HEART PROTECTION; HUMAN; INFLAMMATION; KIDNEY DISEASE; PRESCRIPTION;

EID: 0034941185     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (29)

1. Crofford L J, Lipsky P E, Brooks P, Abramson S B, Simon L S, Van de Putte L B A. Basic biology and clinical application of specific cyclooxygenase inhibitors. Arthritis Rheum 2000; 43:4-13.
2. Mueller R L, Scheldt S. History of drugs for thrombotic disease. Discovery, development and direction for the future. Circulation 1994; 89:432-49.
3. Vane J R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 1971; 231:232-5.
4. Masterer J L, Zweifel B S, Seibert K, Needleman P. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J Clin Invest 1990; 86:1375-9.
5. Smith W L. Prostanoid biosynthesis and mechanisms of action. Am J Physiol 1992; 263:F181-91.
6. Vane J R. Mechanisms of action of NSAIDs. Br J Rheumatol 1996; 35(S):1-3.
7. Douthwaite AH, Lintott GAM. Gastroscopic observation of effect of aspirin and certain other substances on stomach. Lancet 1938; 2: 1222-5.
8. Singh G, Triadafilopouos G. Epidemiology of NSAID-induced GI complications. J Rheumatol 1999; 26(Suppl):18-24.
9. Hernandez-Diaz S, Rodriguez L A G. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding/perforation. Arch Int Med 2000; 160:2093-9.
10. Wolfe M M, Lichenstein D R, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med 1999; 340: 1888-98.
11. Cooke M E, Wallin J D, Thakur V D, Kadowitz P J, McNamara D B. Garcia M M, et al. Comparative effects of nabumetone, sulindac, and ibuprofen on renal function. J Rheumatol 1997; 24:1137-44.
12. Lipsy P E, Abramson S B, Crofford L, DuBois R N, Simon L, Van de Putte L B A. The classification of cyclooxygenase inhibitors. J Rheumatol 1998; 25:2298-303.
13. Dequeker J, Hawkey C, Kahan A, Steinbruck K, Alegre C, Baumelou E, et al. Improvement in gastrointestinal tolerability of selective cyclooxygenase (COX )-2, meloxicam, compared to piroxicam. Results of the Safety and Efficacy Large-Scale Evaluation of COX-inbibiting Therapies (SELECT) Trial in Osteoarthritis. Br J Rheumatol 1998; 37:946-51.
14. Hawkey C, Kahan A, Steinbruck K, Alegre C, Baumelou E, Begaud B, et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. The International MELISSA Study Group. Br J Rheumatol 1998; 37:937-45.
15. Schoenfield P. Gastrointestinal safety profile of meloxicam: A meta-analysis and systematic review of randomized controlled trials. Am J Med 1999; 107(6A):48S-54S.
16. Meloxicam (Mobic): Gastrointestinal and skin reactions. Curr Prob Pharmacovigilance 1998; 24:13.
17. Emery O, Zeidler H, Kvien T K, Guslandi M, Naudin R, Staed H, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomized double-blind comparison. Lancet 1999; 354: 2106-11.
18. Goldstein J L, Silverstein F E, Agrawal N M, Hubbard R C, Kaiser J, Maurath C J, et al. Reduced risk of upper gastrointestinal complications with Celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000; 95:1681-90.
19. Silverstein F E, Faich G, Goldstein J L, Simon L S, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for Osteoarthritis and rheumatoid arthritis: the CLASS study. JAMA 2000; 284:1247-55.
20. Day R, Morrison B, Luza A, Casteneda O, Strusberg A, Nahir M, et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Arch Int Med 2000; 160:1781-7.
21. Cannon G W, Caldwell J R, Holt P, McLean B, Seidenberg B, Bolognese J, et al. Rofecoxib, a specific inhibitor of cyclooxygenase-2 with clinical efficacy comparable with that of diclofenac sodium. Arthritis Rheum 2000; 43:978-87.
22. Hawkey C, Laine L, Simon T, Beaulieu A, Maldonado-Cocco J, Acevedo E, et al. Comparison of the effect of rofecoxib (a cyclooxygenase inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis. Arthritis Rheum 2000; 43:370-7.
23. Langman M J, Jensen D M, Watson D J, Harper S E, Zhao P, Quan H, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999; 282:1929-33.
24. Crofford L J, Oates J C, McCune W J, Gupta S, Kaplan M J, Catela-Lawson F, et al. Thrombosis in patients with connective tissue disease treated with cyclooxygenase 2 inhibitors. A report of four cases. Arthritis Rheum 2000; 43:1891-6.
25. Swan S K, Rudy D W, Lasseter K C, Ryan C F, Buechel K L, Lambrecht L J, et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. Ann Intern Med 2000; 133:1-9.
26. Whelton A, Schulman G, Wallemark C, Drower E J, Isakson P C, Verburg K M, et al. Effects of celecoxib and naproxen on renal function in the elderly. Arch Int Med 2000; 169:1465-70.
27. Charkraborty I, Das SK. Wang J, Dey S K. Dvelopmental expression of cyclooxygenase-1 and cyclooxygenase-2 genes in the peri-implantation mouse uterus and their differential regulation by the blastocyst and ovarian steroids. J Mol Endocrinol 1996; 16:107-22.
28. Quaratino D, Romano A, Di Fonso M, Pap G, Perrone M R, D'Ambrosio F P, et al. Tolerability of meloxicam in patients with histories of adverse reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2000; 84:613-7.
29. Simon L S. Overview of selective COX-2 Inhibitors. UpToDate 8.3 2000.